The 12th Annual Tumor Models is dedicated to predictability & clinical translatability of novel combination, targeted therapies with safety & efficacy.
The 12th Annual Tumor Models covers topics such as:
- Understanding the next steps to overcome combination therapy failure in the clinic by using predictive models more efficiently with Merck
- Model selection criteria dependent on cancer type to enable to streamline your model selection process cost-effectively and time-efficiently
- New data from the immune system and tumor microenvironment to tackle tumor resistance with Dicerna Pharmaceuticals
- Strategies for preclinical and clinical biomarker selection that will empower you to accurately predict drug combination success in patients
- Xilio Therapeutics, Odyssey Therapeutics and Dana-Farber Cancer Institute dive deep through an interactive chat into bridging translatability towards patients
- The 12th Annual Tumor Models brings together:
- Model developers and pharmaceutical scientists
- Preclinical and translational scientists
The 12th Annual Tumor Models will be held in Boston, United States on 17-18 Jul 2024.
